Effect of Caldine® on Renal Function in Balanced Hypertension
Terminated
- Conditions
- Hypertension
- Interventions
- Drug: DiureticsDrug: antihypertensive drugsDrug: alpha blockersDrug: Angiotensin-Converting Enzyme InhibitorsDrug: beta blockers
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5417
- Registration Number
- NCT02240641
Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe
Completed
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36573
- Registration Number
- NCT02240654
- Locations
- 🇪🇸
1160.144.1 Boehringer Ingelheim Investigational Site, Barcelona, Spain
Linagliptin as Add on to Basal Insulin in the Elderly
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 302
- Registration Number
- NCT02240680
- Locations
- 🇯🇵
Jiyugaoka Yamada Clinic, Hokkaido, Obihiro, Japan
🇯🇵Yoshida Memorial Hospital, Hokkaido, Sapporo, Japan
🇺🇸East Coast Institute for Research LLC at NE FL Endo & Diabetes, Jacksonville, Florida, United States
Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients
Phase 2
Terminated
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 79
- Registration Number
- NCT02239835
Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria
Completed
- Conditions
- Urticaria
- Interventions
- Drug: Alesion®
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 122
- Registration Number
- NCT02238249
Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 346
- Registration Number
- NCT02238171
Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 477
- Registration Number
- NCT02238197
Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 595
- Registration Number
- NCT02238158
Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo Diskus®Drug: Placebo HandiHaler®
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 136
- Registration Number
- NCT02238106
Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 374
- Registration Number
- NCT02238132
© Copyright 2025. All Rights Reserved by MedPath